/PRNewswire/ Based on its recent analysis of the Indian in vitro diagnostics (IVD) market, Frost & Sullivan recognizes Roche Diagnostics India with the 2021.
Its technology-centric solutions enable hospitals to enhance operational efficiency and enable faster clinical decision making MUMBAI, India, March 14, 2022 /PRNewswire/ Based on its recent analysis of the Indian in vitro diagnostics (IVD) market, Frost & Sullivan recognizes Roche Diagnostics India with the 2021 India Competitive Strategy Leadership Award for its well-executed country strategies, effective market penetration, and.
Manjira Sharma joins Roche Diagnostics as Head of Communications adgully.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from adgully.com Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
MUMBAI, India and BALTIMORE, Feb. 1, 2021 /PRNewswire/ Lupin Pharmaceuticals Inc. (Lupin), global pharmaceutical company, announced today a partnership with Phil, Inc., which helps deliver cost-effective next-generation access solutions for patients who are prescribed Solosec® (secnidazole) 2g oral granules for the treatment of bacterial vaginosis (BV) in adult women.
Solosec® is the only single 2g oral dose therapy for the most common vaginal infection in the U.S. among adult women. This treatment is designed to deliver a full course of therapy in just one packet.
1 In November, Lupin announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) for Solosec® (secnidazole) for the treatment of trichomoniasis in adults and adolescents. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target date of June 30, 2021.